Cytokinetics, Incorporated (CYTK) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
CYTK Revenue Growth
Revenue Breakdown (FY 2025)
CYTK's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
CYTK Revenue Analysis (2014–2025)
As of May 8, 2026, Cytokinetics, Incorporated (CYTK) generated trailing twelve-month (TTM) revenue of $105.8 million, reflecting explosive growth of +1125.8% year-over-year. The most recent quarter (Q1 2026) recorded $19.4 million in revenue, up 9.0% sequentially.
Looking at the longer-term picture, CYTK's 5-year compound annual growth rate (CAGR) stands at +9.5%, indicating steady revenue expansion. The company achieved its highest annual revenue of $106.4 million in 2016.
Revenue diversification analysis shows CYTK's business is primarily driven by Collaboration Revenues (100%). With over half of revenue concentrated in Collaboration Revenues, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including MDGL (+256.8% YoY), KRYS (+25.1% YoY), and RCUS (+67.4% YoY), CYTK has outperformed the peer group in terms of revenue growth. Compare CYTK vs MDGL →
CYTK Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CYTKCurrent | $106M | +1125.8% | +9.5% | -695.4% | |
 MDGL | $958M | +256.8% | - | -31.3% | |
 KRYS | $389M | +25.1% | - | 41.5% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% |
CYTK Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $88.0M | +376.6% | $77.9M | 88.5% | $-612,258,000 | -695.4% |
| 2024 | $18.5M | +145.3% | $-320,934,000 | -1737.2% | $-536,248,000 | -2902.7% |
| 2023 | $7.5M | -92.0% | $-322,593,000 | -4284.1% | $-496,205,000 | -6589.7% |
| 2022 | $94.6M | +34.3% | $-146,225,000 | -154.6% | $-324,202,000 | -342.8% |
| 2021 | $70.4M | +26.2% | $-89,510,000 | -127.1% | $-186,313,000 | -264.5% |
| 2020 | $55.8M | +107.8% | $-41,123,000 | -73.7% | $-93,943,000 | -168.3% |
| 2019 | $26.9M | -14.7% | $-59,257,000 | -220.5% | $-98,867,000 | -368.0% |
| 2018 | $31.5M | +135.6% | $-57,634,000 | -183.0% | $-88,916,000 | -282.3% |
| 2017 | $13.4M | -87.4% | $-76,928,000 | -575.5% | $-113,396,000 | -848.3% |
| 2016 | $106.4M | +271.3% | $42.0M | 39.5% | $18.7M | 17.6% |
See CYTK's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CYTK Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CYTK vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCYTK — Frequently Asked Questions
Quick answers to the most common questions about buying CYTK stock.
Is CYTK's revenue growth accelerating or slowing?
CYTK revenue is accelerating at +1125.8% year-over-year, exceeding the 5-year CAGR of +9.5%. TTM revenue reached $106M. Growth momentum has increased versus prior periods.
What is CYTK's long-term revenue growth rate?
Cytokinetics, Incorporated's 5-year revenue CAGR of +9.5% reflects the sustained expansion pattern. Current YoY growth of +1125.8% is above this long-term average.
How is CYTK's revenue distributed by segment?
CYTK reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.